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ABSTRACT
Stem cell-based regenerative therapies hold great potential for the treatment of degenerative disor-
ders such as Parkinson’s disease (PD). We recently reported the repair and functional recovery after
treatment with human marrow-isolated adult multilineage inducible (MIAMI) cells adhered to
neurotrophin-3 (NT3) releasing pharmacologically active microcarriers (PAMs) in hemiparkinsonian
rats. In order to comprehend this effect, the goal of the present work was to elucidate the survival,
differentiation, and neuroprotectivemechanisms ofMIAMI cells and human neural stem cells (NSCs),
both adhering to NT3-releasing PAMs in an ex vivo organotypic model of nigrostriatal degeneration
made frombrain sagittal slices. Itwas shownthatPAMs led toamarked increase inMIAMI cell survival
and neuronal differentiation when releasing NT3. A significant neuroprotective effect of MIAMI cells
adhering to PAMs was also demonstrated. NSCs barely had a neuroprotective effect and differenti-
atedmostly intodopaminergic neuronal cellswhenadhering to PAM-NT3.Moreover, those cellswere
able to release dopamine in a sufficient amount to induce a return to baseline levels. Reverse
transcription-quantitative polymerase chain reaction and enzyme-linked immunosorbent assay anal-
yses identified vascular endothelial growth factor (VEGF) and stanniocalcin-1 as potential mediators
of the neuroprotective effect of MIAMI cells and NSCs, respectively. It was also shown that VEGF lo-
cally stimulated tissue vascularization, whichmight improve graft survival, without excluding a direct
neuroprotective effect of VEGF on dopaminergic neurons. These results indicate a prospective inter-
est of human NSC/PAM and MIAMI cell/PAM complexes in tissue engineering for PD. STEM CELLS
TRANSLATIONAL MEDICINE 2015;4:670–684
SIGNIFICANCE
Stem cell-based regenerative therapies hold great potential for the treatment of degenerative dis-
orders such as Parkinson’s disease (PD). The present work elucidates and compares the survival, dif-
ferentiation, and neuroprotective mechanisms of marrow-isolated adult multilineage inducible cells
and human neural stem cells both adhered to neurotrophin-3-releasing pharmacologically active
microcarriers in an ex vivo organotypic model of PD made from brain sagittal slices.
INTRODUCTION
Parkinson’s disease (PD) is an incurable neuro-
degenerative disorder, characterized by the
progressive degeneration of the nigrostriatal do-
paminergic system, that leads to a severe dopa-
mine (DA) deficiency in the striatum required
for motor control [1]. Clinical trials with dopami-
nergic fetal tissue transplantation have shown
the efficacy of this strategy but also its limits, in
particular, poor cell availability [2, 3]. Among
the different stem cell sources, neural stem cells
(NSCs), which differentiate into neuronal cells
and improve the motor behavior of parkinsonian
rats, hold great promise for PD cell therapy [4–7].
Another possible cell source is an easily accessible
homogeneous, humanmesenchymal stromal cell
(MSC) subpopulation named marrow-isolated
adult multilineage inducible (MIAMI) cells that
express pluripotent stem cell markers, have
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a potential for neuron-like differentiation, and secrete tissue re-
pair factors [8–12]. NSC and MSC populations have been ev-
aluated in PD clinical trials that demonstrated the feasibility,
safety, and efficacy of the therapeutic strategy [13–16]. However,
despite these encouraging results, stem cell-based therapies for
PD face low cell survival, differentiation, and engraftment, limit-
ing their effectiveness and use [17, 18].
The development of new tools able to enhance cell therapy
potential is needed. In this context, pharmacologically active
microcarriers (PAMs), which provide a three-dimensional biomi-
metic support to the cells and mediate sustained release of cyto-
kines, have been shown to be beneficial in several animal models
of different brain disorders, including PD and cerebral ischemia
[12, 19–22]. We have previously demonstrated that the striatal
implantation ofMIAMI cells, precommitted toward a dopaminer-
gic phenotype and adhering to laminin-coated PAMs releasing
neurotrophin-3 (LM-PAM-NT3), induced significant nigrostriatal
pathway repair and functional recovery in a rat model of PD,
partly by their increased survival and tyrosine hydroxylase (TH)
expression [12]. However, to be successfully translated to the
clinic, additional studies are needed to fully understand the MI-
AMI cells’ and NSCs’ mode of action and to elucidate the contri-
bution of PAMs to neural repair and regeneration.
Organotypic cultures made from brain slices, which can be
maintained in culture for several weeks, canmodel the patholog-
ical neurodegenerative disease state, allowing one to test the
stem cell potential in a PD context (reviewed in [23]). Our group
has previously developed a novel organotypic PDmodel from the
rat brain that includes all the areas involved in the nigrostriatal
pathway in a single slice preparation, without using neurotoxins
to induce the dopaminergic lesion. This physiologically relevant
model allows the observation of cellular interactions and mech-
anisms, using small amounts of material, and represents a prom-
ising tool to better understand and refine new therapeutic
approaches [23, 24].
In the present work, we aim at elucidating the survival, differ-
entiation, and neuroprotective mechanisms of both MIAMI cells
and NSCs and the contribution of NT3-releasing PAMs when the
cell/PAM three-dimensional complexes are transplanted in an ex
vivo model of nigrostriatal degeneration. We first assessed the
protection/repair potential of NSCs and MIAMI cells, associated
or not with PAMs, after grafting in the ex vivo model of PD. Stem
cell survival and proliferation and their neuronal and dopaminer-
gic differentiation capacity were next studied with the cells
administered alone or combined with PAMs, to evaluate their
mechanisms of action and the contribution of PAMs. Finally, neu-
roprotectivemechanismswere clarified by studying the secretory
phenotype of the cells and the paracrine-mediated impact on the
organotypic slice microenvironment.
MATERIALS AND METHODS
An extended section is available in the supplemental online data.
Ethics
To overcome the ethical limitations associated with human em-
bryonic NSCs, a cell line of human NSCs, namely hNS1, was used.
MIAMI cells were obtained from a human postmortem donor or-
gan (withagreement fromtheFrenchAgencyofBiomedicine). An-
imal care and use were in strict accordance with the regulations
of the French Ministry of Agriculture. All animal procedures
were approved by animal experimentation ethic committee of
Pays de la Loire.
Cell Culture
Culture of MIAMI Cells
HumanMIAMI cells were isolated from a 20-year-old male donor
and expanded in vitro, as previously described [8, 25].
Culture of NSCs
hNS1 cells, a cell line of humanNSCs of forebrain origin expressing
green fluorescent protein (GFP) [26, 27], were expanded in vitro
from passage 10 to 15 on poly-D-lysine (PDL, Sigma-Aldrich,
St. Louis, MO, http://www.sigmaaldrich.com)-coated flasks [26].
This cell line spontaneously generates neuronal cells after mito-
gen removal and intracerebral transplantation [28, 29] and differ-
entiates into dopaminergic neurons when micrografted into rat
striatal brain slices [30].
Obtaining and Culturing Parkinson’s Disease
Organotypic Slices
Organotypic cultureswere prepared as previously described [24].
PAM Formulation and Characterization
Formulation of PAMs
NT3-loaded microspheres were prepared using a solid/oil/water
emulsion solvent extraction-evaporation method [12, 31]. A poly
(lactic-coglycolic acid) (PLGA) copolymer with a lactic/glycolic ra-
tio of 37.5:25 (molecular weight, 25,000 Da) (Phusis, Saint Ismier,
France) was used.
To obtain LM-PAMs, PLGAmicrosphereswere coated by incu-
bation with a combination of LM and PDL molecules (both from
Sigma-Aldrich) at a final concentration of 6mg/ml PDL and 9mg/ml
LM [12, 32, 33].
Release Profile and Bioactivity of Released Protein
From LM-PAM-NT3
To assess NT3 release kinetics, 5 mg of LM-PAM-NT3 was dis-
persed on 500 ml of medium. Every day from day 1 to day 5 and
thereafter every 3 days, the sample was centrifuged at 295g for
10 minutes. The supernatants were collected and stored at220°C
before bioassay.
The bioactivity of NT3 released from the LM-PAM-NT3 was
evaluated in vitro by determining the extension of the cellular
process of dorsal root ganglion (DRG) cells after NT3 treatment
(n = 2).
Formation of PAM/Stem Cell Complexes
Cell/PAM complexes were prepared as previously described
[32–35]. Cell adhesion to the PAM surfacewas assessed bymicro-
scopic observation, and the cells adhering to PAMs were quanti-
fied using a Cyquant cell proliferation assay kit (Invitrogen,
Carlsbad, CA, http://www.invitrogen.com). Complexes were
studied further using fluorescence microscopy for NSCs and
scanning electron microscopy for MIAMI cells [20].
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Injection of Stem Cell/PAM Complexes Into
Organotypic Slices
Twodays after organotypic slice preparation, the cells/complexes
constitutingdifferent treatment conditionswere injected into the
striatum using a 22-gauge needle (Hamilton, Bonaduz, Switzer-
land, http://www.hamiltoncompany.com) connected to a micro-
manipulator (Fig. 1A). Nine experimental groups were evaluated.
For each experimental group, three independent experiments
were performed, unless otherwise stated. The total injection vol-
ume consisted of 2 ml of culture medium containing approxi-
mately 50,000 cells alone or adhering to 0.1 mg of PAMs. The
injections were done at an infusion rate of 0.5 ml/minute. The
needle was left in place for 5 minutes before removal to avoid
the cells being expelled from the organotypic slices.
Histological Study
At 1 and 14 days after injection (Fig. 1A), the organotypic slices
were fixed with 5 ml of ice cold 4% paraformaldehyde (Sigma-
Aldrich) in phosphate-buffered saline (PBS) (Lonza, Walkersville,
MD, http://www.lonza.com) (pH 7.4) for 2 hours at 4°C. Next, the
slices werewashedwith PBS. Nonspecific sites were blockedwith
PBS, Triton 1% (PBS-T, Triton X-100; Sigma-Aldrich), bovine serum
albumin (BSA) 4% (Fraction V; PAA Laboratory), and normal goat
serum 10% (Sigma-Aldrich) for 4 hours at room temperature un-
der agitation. For CD31 study, 0.05% Triton was used.
Tyrosine Hydroxylase Immunochemistry
Two antibodies (mouse anti-rat TH [10mg/ml in PBS-T, clone 6D7,
Covance, Emeryville, CA, http://www.covance.com], for endoge-
nous nigrostriatal pathway analysis, and polyclonal rabbit anti-
human TH [1:100, AS-DOUB-LX immunization program, Lie`ge,
Belgium], to assess the catecholaminergic/dopaminergic differ-
entiation of grafted human stem cells) were used as described
in the supplemental online data. TH-positive rat fiber and hu-
man TH-positive fiber quantification was performed using Meta-
morph software (Molecular Devices, Sunnyvale, CA, http://www.
moleculardevices.com).
Anti-Mitochondria, b3-Tubulin, Ki67, and
CD31 Immunofluorescence
MIAMIcellsweredetectedusingamouseanti-humanmitochondria
antibody (10 ng/ml,mitochondrial cytochromeCoxidase subunit II;
Abcam, Cambridge, U.K., http://www.abcam.com).GFP-NSCswere
directly observed under fluorescence microscopy. Mouse anti-
human b3-tubulin (2 ng/ml, SDL.3D10; Sigma-Aldrich) or rabbit
monoclonal anti-b3-tubulin (1:400, EP1331Y; Abcam), mouse
anti-human CD31 (300 ng/ml, WM59; BD Pharmingen, Franklin
Lakes, NJ, http://www.bdbiosciences.com) andmonoclonal mouse
anti-humanKi67 (350ng/ml,MIB-1;Dako,Glostrup,Denmark, http://
www.dako.com) antibodies were used to characterize grafted cell
differentiation. Mouse anti-rat CD31 antibody (10 mg/ml,
TLD-3A12; Abcam, Paris, France) was used to analyze brain slice
vascularization. The slices were incubated for 48 hours with the
first antibody in PBS-T, BSA 4% at 4°C. The washed slices were incu-
bated with the corresponding biotinylated mouse or rabbit second
antibody (7.5 mg/ml; Vector Laboratories, Burlingame, CA, http://
www.vectorlabs.com). The slices were washed and incubated with
streptavidin fluoroprobes R488 or R547H (Interchim, Montluçon,
France, http://www.interchim.com) diluted 1:200 in PBS for 2 hours
beforemountingwitha fluorescentmountingmedium. Isotypic con-
trols and/or primary antibody omission were performed to assess
specificity.
The intensity and density of the positive stained cells were
quantified usingMetamorph software. Colocalizations were con-
firmed using confocal microscopy.
Molecular Study
Dopamine Quantification by Mass Spectrometry
Quantification of DA in the striatum at days 0 and 16 was per-
formed as previously described [24] and was expressed as the
DA content per milligram of striatum.
Laser Microdissection
At 24 hours after implantation (Fig. 1A), cells grafted alone or
complexedwith PAMswere isolated from the striatumusing laser
microdissection (LMD). Organotypic slices were dehydrated by
4 successive 4-minute ethanol baths (70°, 90°, 100°, and 100°).
Immediately after slice dehydration, microdissection was per-
formed at room temperature with the LMD6000microdissection
system and software from Leica (Leica Microsystems, Wetzlar,
Germany, http://www.leica-microsystems.com), using a UV laser
with a wavelength of 355 nm. The microdissection settings were
as follows: power128; speed1; specimenbalance0; andobjective
6.33. Areas of approximately 12 mm2, corresponding to the
whole striatum, were collected in 70 ml of RNA Later (Life Tech-
nologies, Carlsbad, CA, http://www.lifetechnologies.com). Stria-
tum from2 organotypic slices were pooled, centrifuged, and kept
at280°C until RNA extraction.
Reverse Transcription and Real-Time Quantitative
Polymerase Chain Reaction
The design of primers specific for human genes and polymerase
chain reaction (PCR) were performed as described previously
[10, 12] (Table 1). Reverse transcription-quantitative polymerase
chain reaction (RT-qPCR) was performed as previously described
[10, 12, 35]. Several housekeeping genes were tested for normal-
ization. The relative transcript quantity was determined using the
DCt method, and relative quantities were normalized using the
multiple normalization method [36].
Enzyme-Linked Immunosorbent Assays
Every 2 days, from day 0 to day 16, slice culture media were col-
lected and stored at280°C until use. Enzyme-linked immunosor-
bent assays (ELISAs) were performed to detect grafted cell
secretion of human stanniocalcin-1 (hSCT-1) and human vascular
endothelial growth factor (DuoSet ELISA and hVEGFA, specific to
the 121, 165a, and 165b forms, DuoSet ELISA; both fromR&DSys-
tems,Minneapolis,MN, http://www.rndsystems.com), following
the manufacturer’s instructions. Three independent samples
were tested in triplicate.
Statistical Analysis
The data are presented as the mean value of three independent
experiments 6SD, unless otherwise stated. Significant differen-
ces between the samples were determined using an analysis of
variance test, followed by a Scheffe´ post hoc test, which indicated
whether the conditions were significantly different. The p value
was ,.05, unless otherwise stated.
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Figure 1. Experimental protocol and characterization of stem cells and PAMs alone and associated. (A): Experimental protocol. At day 0, the
nigrostriatal pathway remains intact but degeneration is initiated. Two days after slice preparation, cell-PAM complexes were transplanted in
the striatum. At day 3 (1 day after grafting), the grafted cells’ fate and growth factor expressionwere analyzed. At day 16 (14 days after grafting),
dopaminergic degeneration is complete. The grafted cells’ fate and host tissue responses were also studied at this time point. (B): RT-qPCR
against NT3 receptors for MIAMI cells and NSCs in vitro. Both types of cells express NT3 receptor mRNA, in particular, NSCs. Housekeeping
genes GAPDH, HPRT1, ACTB, RSP18, and HSPCB were used for normalization (supplemental online data). (C): Observation of microparticles
by bright field microscopy. Microparticles were perfectly spherical with a smooth surface and a mean diameter of 60 mm. Scale bar = 50 mm.
(D): DRG neurons observed by immunofluorescence against b3-tubulin. (Left) A nontreated DRG neuron and (Right) a DRG neuron cultured
with 5 ng/ml NT3, exhibiting extended processes. Scale bar = 30 mm. (E): Number of DRG neurons with extended processes. The released NT3
was bioactive and was equivalent to approximately 5–10 ng/ml compared with the recombinant control. (F): Observation of PAMs by scanning
electronic microscopy when complexed with MIAMI cells and by fluorescence microscopy when complexed with GFP-positive NSCs. Scale bars =
10mm (MIAMI-PAM) and = 60mm (NSC-PAM). Abbreviations: D, day; DRG, dorsal root ganglion; GFP, green fluorescent protein; hNSCs, human
neural stem cells;MIAMI,marrow-isolated adultmultilineage inducible (cell); NSC, neural stem cell; NT3, neurotrophin-3; NTRK3, neurotrophic
kinase receptor, type 3; PAM, pharmacologically active microcarrier; RT-qPCR, reverse transcription quantitative polymerase chain reaction;
Tkd-NTRK3, tyrosine kinase-deficient isoform of NTRK3.
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RESULTS
Stem Cell NT3 Receptor Expression
Neurotrophic kinase receptor type 3, which represents all NT3 re-
ceptor variants and the tyrosine kinase-deficient isoform, were
expressed in both NSCs and MIAMI cells, suggesting that both
stem cells might respond to this neurotrophin and confirming
previous reports [12]. Furthermore, NT3 receptor expression
was 10-fold higher in NSCs than in MIAMI cells (Fig. 1B).
Characterization of PAMs
The mean LM-PAM size was 60.92 6 20.04 mm. Observation of
microspheres and PAMs under bright field and scanning electron
microscopy showed that they were perfectly spherical, with a
smooth surface and no pores on their surface (Fig. 1C). The NT3mi-
croencapsulation yield was approximately 100%, determined using
the NanoOrange total protein assay (Life Technologies).
The amount of bioactive NT3 released from PAMs was quan-
tified using a bioassay based on rat DRG cell process extension
(Fig. 1D). The released NT3 was bioactive and was equivalent
to approximately 3.5–10 ng/ml compared with the recombinant
control. After considering the dilution of the collected samples,
this corresponded to approximately 185 ng NT3 per milligram
PAMduring the first day, constituting the burst release. Next, ap-
proximately 11–30 ng of NT3 per milligram of PAM was released
for each time period examined (Fig. 1E). Furthermore, NT3 con-
tained within the PAMs was bioactive 8 months after PAM prep-
aration when conserved lyophilized at220°C (data not shown).
The stem cells adhered to PDL/LM PAMs as observed by fluo-
rescence microscopy and scanning electron microscopy and
formed 3D cell/PAM complexes (Fig. 1F). The percentage of cells
adhering to PAMs’ surface at the end of the cell attachment pro-
tocol was approximately 94%.
Effects of Grafted Stem Cell/PAM Complexes on the
Organotypic Nigrostriatal Pathway
Nigrostriatal Pathway Repair/Protection
Immunohistochemistry against rat TH was used to assess both
nigrostriatal lesions in the organotypic slice and therapeutic
benefits of treatment strategies (Fig. 1A). A decrease in TH fiber
density in the striatum of nontreated slices was observed over
time (Fig. 2A). A day 0 slice exhibited a TH density of 100%. The
density had reached 40% at day 3 and 0% at day 16, confirming
the findings of a previous report [24]. Implantation of LM-PAM-
NT3 or NSC/LAM-PAM-NT3 induced only a slight recovery of TH
expression, which was greater after MIAMI cell/LM-PAM-NT3
grafting (Fig. 2A). The quantification indicates that, after implan-
tation of MIAMI cells/LM-PAM-NT3, the TH fiber density signifi-
cantly increased (Fig. 2C) and reached 77% of the intact slice
compared with the degenerated slice. For all other conditions
tested, the density varied from approximately 30% to 65%
(Fig. 2C). The regions of interest can be observed in supplemental
online Figure 1A.
In the nontreated slices, TH-positive fiberswithin themedial
forebrain bundle (MFB) were observed 1 day after organotypic
slice preparation. However, no TH staining within the MFB
could be detected after 16 days in culture, showing the dopami-
nergic neuron degeneration. Fourteen days after NSCs or
MIAMI cell transplantation, both were adhering to LM-PAM-
NT3, the dopaminergic fiber degeneration within the MFB
was less significant, and dopaminergic fibers with some varicos-
ities could be observed. In contrast, LM-PAM-NT3 injected
alone did not seem to protect those dopaminergic fibers
(Fig. 2B).
Striatal Dopamine Levels
The striatal DA level was quantified to assess the grafted cells
striatal DA content restoration. A statistically significant reduc-
tion of 80% in striatal DA content (from 17.9 to 3.3 pg/mg tissue)
wasdetected3daysafter slice culture comparedwith theday0 in-
tact slices. The DA content remained low until day 16, confirming
our previous results [24]. The injection of MIAMI cells alone or
complexed to LM-PAM-NT3 induced a slight DA recovery, which
wasnotdifferent comparedwith anegative control. However, the
striatal DA content of an organotypic model of PD grafted with
NSCs, adhering or not to PAMs, had remarkably reached normal
levels 14 days after grafting, with a dopamine concentration of
18 pg/mg tissue (Fig. 2D).
Table 1. Gene primers used for RT-qPCR
Gene Full name Accession number Sequence
BDNF Brain-derived neurotrophic factor 000011.9 Qiagen, reference no. QT00235368
GDNF Glial cell line-derived neurotrophic factor 011675.2 Qiagen, reference no. QT00001589
HGF Hepatocyte growth factor 001010934 F = 59-TCTGGTTCCCCTTCAATAGC-39
R = 59-GTGTTCGTGTGGTATCATGG-39
NT3 Neurotrophin-3 001102654.1 Qiagen, reference no. QT00204218
NGF Nerve growth factor 002506 Qiagen, reference no. QT00043330
VEGFA Vascular endothelial growth factor A 001204384 F = 59-CAGCGCAGCTACTGCCATCCA-39
R = 59-CAGTGGGCACACACTCCAGGC-39
STC1a Stanniocalcin-1 003155 F = 59-AGGCAAGGCTGACTTCTCTG-39
R = 59-AACTACTTGTCGCATTGGGG-39
NTRK3 Neurotrophic tyrosine kinase, receptor,
type 3, Variant A
AF058389.1 F = 39GAACCTCTACTGCATCAACG-59
R = 39ACTATCCAGTCCACATCAGG-59
TKd-TRK3 Neurotrophic tyrosine kinase, receptor,
type 3 transcript variant 3 (isoform C)
AF058390.1 F = 39AGCCGGACACGTGGGTCTTTT-59
R = 39CTTGGAATGTCCGGGAAGGCTTA-59
Abbreviations: F, forward; R, reverse.
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Fate of Stem Cell/PAM Complexes After Injection in
Organotypic Cultures
Morphology
Human-specificmitochondria (hMito) forMIAMI cells andGFPex-
pression for NSCs were used to evaluate the fate, survival, and in-
tegration of stem cells injected alone or combined with PAMs in
the organotypic model of PD (Fig. 1A). One day after intrastriatal
implantation, theNSCs andMIAMI cells exhibited a round-shaped
morphology typical of undifferentiated stem cells (supplemental
online Fig. 1B, 1C, left). Fourteendays after grafting, the stemcells
remained adhered to PAMs and circumscribed within the stria-
tum (Fig. 3B, 3E). At this time point, the NSCs showed a neu-
ron-like morphology with significant neurite outgrowth, and
the MIAMI cells exhibited a bipolar neuron-like morphology
(supplemental online Fig. 1B, 1C, right).
Survival and Proliferation of Grafted Cells
At 24hours after implantation, a slight increase inGFP-expressing
NSCswasobserved in the slices graftedwithNSC/PAMcomplexes
compared with NSCs grafted alone (Fig. 3A, 3C). After 14 days, no
differences in the density of GFP-expressing NSCs were found
when the cells were grafted alone or combined with PAMs (Fig.
3A, 3C). In contrast, more hMito-expressing cells were observed
when the MIAMI cells adhering to PAMs were grafted at both
time points (Fig. 3E, 3F). Quantification of hMito-positive cells
within the striatum showed that both types of PAMs signifi-
cantly increased, by 2-fold and 3.3-fold, stem cell survival 1 day
and 14 days after transplantation, respectively (Fig. 3F).
Onedayafter grafting,manyof theGFP-expressingNSCswere
double-labeled for Ki-67, a cell cycle-related nuclear protein, in-
dicating that a proportion of the cells continued to proliferate
at a similar proportion whether adhering or not to PAMs (Fig.
3B, 3D). However, a strong decrease in cell number and Ki-67
expression was observed for all conditions 2 weeks after injec-
tion (Fig. 3B, 3D). No significant differences were found for
these parameters when the cells were adhered to LM-PAMs
or LM-PAM-NT3. These results indicate that most of the cells
stopped proliferating, which suggests that cells can enter into
a process of differentiation over time. For the MIAMI cells, no
evident cell proliferation was detected at both time points
(data not shown).
Figure 2. Protection/repair of the nigrostriatal pathway at day 16. (A): TH immunochemistry of St/Cx tissue. In intact slice, strong staining is
observed compared with Cx, which represents the background. A total disappearance of TH staining was observed for the negative control,
and injection of LM-PAM-NT3 injected alone or NSC/LM-PAM-NT3 induces only a slight recovery. For MIAMI/LM-PAM-NT3 injections, a TH
staining can be observed highlighting a protection of the dopaminergic fibers. Scale bar: 100mm. (B): TH immunochemistry of MFB dopa-
minergic fibers at day 16. A total disappearance of the fibers was observed for negative control and for LM-PAM-NT3 injected alone while
injection of MIAMI/LM-PAM-NT3 complexes or NSC/LM-PAM-NT3 complexes protected TH+ fibers in comparison with degenerated slice.
Scale bar = 100 mm. (C): Quantification of rat TH density in the organotypic striatum. A significant increase of rat TH+ fiber density was ob-
served after MIAMI/LM-PAM-NT3 treatment compared with the degenerated slice (n = 3; p , .05). (D): Quantification of the striatal do-
pamine content per mass of tissue in percentages. A slight increase in dopamine content was observed after MIAMI cell injection, and
a remarkable increasewas observed after NSC implantation. Dopamine content was quite similar when adherent cells were implanted alone
or combined with LM-PAMs or LM-PAM-NT3 (n = 2). Abbreviations: LM, laminin; MFB, medial forebrain bundle; MIAMI, marrow-isolated
adult multilineage inducible (cell); NSC, neural stem cell; NT3, neurotrophin-3; PAM, pharmacologically active microcarrier; St/Cx, striatal/
cortex; TH, tyrosine hydroxylase.
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Figure 3. Stem cell survival and proliferation. (A): GFP-expressing NSCs, day 16, survival. hNS1 cells observed by fluorescence microscopy
14 days after grafting alone (left) or complexed with PAMs (right). No significant differences in GFP expression were noticed. Scale bar = 100 mm. (B):
GFP expressing NSCs, days 1 and 16, Ki-67 expression. Immunofluorescence against human Ki-67 (red), highlighting the proliferation of grafted
hNS1 cells 1 day (left) and 16 days (right) after grafting when complexed to PAMs. A significant decrease in Ki-67 expression was observed over
time. PAMs are indicated by asterisks. Scale bar = 100 mm. (C): Quantification of GFP expression by hNS1 cells. A significant decrease in GFP
expression was noticed 14 days after grafting when NSCs were complexed to PAMs. p, p, .05. (D):Quantification of Ki-67 expression by hNS1
cells. A significant decrease in Ki-67 expression was noticed 14 days after grafting when NSCs were complexed to PAMs. p, p, .05. (E):MIAMI
cells, day 16, survival. Immunofluorescence against hMito 14 days after graftingMIAMI cells alone (above) or combinedwith PAMs (below). An
increase in hMito-positive cells was noticed when cells were adhering to PAMs. PAMs are indicated by asterisks. Scale bar = 100mm. (F):Quan-
tificationofhMito-positiveMIAMI cells, day16.After 1and14days in situ, theMIAMIcell number increased2or3 timeswhenadhering toPAMs.
pp, p, .01 (n = 3). For all those experiments, similar results were obtained when cells were implanted with LM-PAMs or LM-PAM-NT3. Abbre-
viations: D, day; GFP, green fluorescent protein; hMito, human-specific mitochondria; LM, laminin;MIAMI, marrow-isolated adult multilineage
inducible (cell); NSC, neural stem cell; NT3, neurotrophin-3; PAM, pharmacologically active microcarrier.
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Differentiation of Grafted Cells to a Neuronal
Dopaminergic Phenotype
At any time point and for any treated group, the number of b3-
tubulin-positive cells, a neuronal marker, was 10 times higher for
NSCs than for MIAMI cells (Fig. 4A, 4B). Notably, at day 14, for
both types of stem cells, the fraction of b3-tubulin-positive cells
increased when the cells were adhering to LM-PAMs and was
even higher when adhering to LM-PAM-NT3 compared with cells
grafted alone. A significant ninefold increase was observed when
the MIAMI cells were adhering to LM-PAM-NT3. Finally, for
NSCs, the fraction of b3-tubulin-positive cells also increased
within the NSC/LM-PAM-NT3 grafted cells between days 1 and
14 (Fig. 4A–4C).
Immunohistochemistry against human-specific TH (hTH), the
rate-limiting enzyme in DA synthesis, illustrates the differentia-
tion of grafted cells toward a neuronal dopaminergic-like pheno-
type (Fig. 4D, 4E; negative control in supplemental online Fig. 1B).
Quantification of hTH+ cells 1 day after injection only showed
a small number of positive cells at this early time point. However,
an overall trend toward a dopaminergic-like phenotype was ob-
served when stem cells were complexed to LM-PAM-NT3. Stem
cell dopaminergic-like differentiation was more evident 14 days
after cell injection,where thenumber of dopaminergic-like differ-
entiated cells had significantly increased by threefold for cells
alone (Fig. 4F). Human TH expression increased twofold when
both stem cells were administrated combined with LM-PAM-
NT3 (reached more than 300 TH-positive for NSCs and 250
TH-positive for MIAMI cells), although the differences were not
statistically significant for the MIAMI cells.
Repair and Protection Mechanisms
In Vitro and Ex Vivo mRNA Expression of Tissue
Repair Factors
In vitro, NSCsmainly expressed hVEGFA and brain-derived neuro-
trophic factor (BDNF), and nerve growth factor (NGF) was ex-
pressed at a lower level (data not shown) (supplemental online
Fig. 2A). The MIAMI cells expressed very high levels of hVEGFA
(about 20-fold more than that of NSCs) and BDNF and low levels
of glial cell line-derived neurotrophic factor (GDNF) and NGF
(supplemental online Fig. 2B), confirming previous results [12].
The hNS1 cell hVEGFA expression was slightly increased 24 hours
after adhesion to LM-PAMs and was almost doubled for MIAMI
cells (supplemental online Fig. 2A, 2B).
At 24 hours after implantation in the lesioned striatum, a
complementary study was performed ex vivo, also with two sup-
plemental primers, hepatocyte growth factor (HGF) and STC-1, af-
ter lasermicrodissectionof grafted complexes. Just as observed in
vitro, NSCs expressed hVEGFA and STC-1. A slight increase in
hVEGFA expression was observed when NSCs were adhering to
PAMs (Fig. 5A). MIAMI cells expressed hVEGFA, HGF, and GDNF,
with a slight decrease in expression when complexed with PAMs
(Fig. 5B). MIAMI cells expressed hVEGFA mRNA, almost 4- to 10-
fold more than that of NSCs (Fig. 5C), although NSCs expressed
40- to100-foldmoreSTC-1mRNAthandid theMIAMI cells (Fig. 5D).
Analysis of Secreted STC-1 and hVEGFA Proteins in
Slice Cultures
NSCssecreted2,3506170pg/mlSTC-1atday3and310670pg/ml
at day 16 (Fig. 5E). Because the MIAMI cells expressed very low
STC-1 mRNA levels, no ELISAs were performed on those cells for
this protein. However, 103 6 20 pg/ml hVEGFA was secreted
by MIAMI cells at day 5, which had significantly decreased to
546 7 pg/ml at day 16. In addition, hVEGFA secretion decreased
when the MIAMI cells adhering to LM-PAM-NT3 were implanted
compared with cells grafted alone at all time points. hVEGFA se-
cretion was very low for NSCs (almost sixfold lower than that of
MIAMI cells) and increased slightly when adhering to LM-PAM-
NT3 (Fig. 5F).
CD31 Expression and Blood Vessels Counting in
Organotypic Slices
The paracrine stem cell-mediated effect of hVEGFA on endothe-
lial cells around the graft area was assessed by CD31 immunoflu-
orescence (Fig. 6A). CD31+ blood vessels and their branches were
quantified in thenigrostriatal slices fromday0 today16of culture
(Fig. 6B). At day 0, thenumber of blood vesselswas approximately
76 3 and had decreased to almost 0 from day 4 to day 16, sug-
gesting the disappearance of vascularization in the organotypic
slices when no treatment was administered. Medium injection
did not induce an increase in blood vessel numbers nor did LM-
PAM-NT3 when grafted alone (data not shown). In contrast,
graftedMIAMI cells induced an increase of CD31 expression, sug-
gesting angiogenesis and blood vessel maintenance. Moreover,
the number of vessels increasedwhenMIAMI cellswere adhering
to PAMs, becoming statistically significant when the cells were
adhering to LM-PAM-NT3 at days 3 and 16. Therefore, the treat-
ment withMIAMI cell LM-PAM-NT3 promoted the normalization
ofbloodvessel number in theorganotypicmodel of PD. This effect
however, was not observed with NSCs alone or when complexed
to PAMs (Fig. 6A, 6B).
DISCUSSION
Cell therapies have failed to demonstrate consistent benefits in
clinical trials of PD. In addition, combinatorial cell and drug deliv-
ery strategies still need to be refined to improve cell engraftment
and differentiation. Therefore, efforts at understanding stem cell
mechanisms, including angiogenesis, neuroprotection, modula-
tion of inflammation, among others, are essential to successfully
translate tissue-engineering approaches into the clinic. In the
present study, the biological mechanisms by which MIAMI cells
and NSCs, complexed or not with LM-PAM-NT3, induce neuro-
protection were elucidated in part using an ex vivo model of
PD. We showed that LM-PAM-NT3 enhanced the dopaminergic
differentiation of NSCs secreting DA, which possessed a modest
neurorepair/protection potential, In contrast, LM-PAM-NT3 en-
hanced survival and differentiation of neural-specified MIAMI
cells into dopaminergic-like cells, inducing a strong neurorepair
that appears to be mediated at least by VEGFA secretion.
MIAMI cells were chosen for our study because they can be
used for autologous implantation directed at the repair of dam-
aged tissues. These cells have been previously characterized
in 3- to 72-year-old donors, and it has been shown that MIAMI
cell properties (e.g., proliferation, differentiation) were mini-
mally affected by donor age and gender [8], making them an
ideal candidate for neuron replacement therapy. Human NSCs
represent an interesting therapeutic alternative. For thepresent
study, an immortalized lineage of hNSCs expressing GFP, with
a normal karyotype and no signs of transformation, disruption,
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Figure4. Differentiationpotential of grafted cells.b3-tubulinexpressionofGFPexpressinghSN1 (A)andhMito-counterstainedMIAMI cells (B)
at day 16. Both cell types were implanted alone (left) and adherent to LM-PAM-NT3 (right) and observed by immunofluorescence 14 days after
grafting.White arrows indicateb3-tubulin-positive cells. Scalebar=50mm. (C):b3-Tubulin expressionquantificationof graftedNSCsandMIAMI
cells 1 and 14days after graftingwhen adherent or not to PAMson fold increase against cells grafted alone at day 1. hNS1 asMIAMI cells showed
a significant expression ofb3-tubulin after 14 days in situ when complexed with LM-PAM-NT3 (n = 3; p, p, .05). Human TH expression of NSCs
(D) and MIAMI cells (E) at day 16. Both cell types were grafted alone (left) and when adherent to LM-PAM-NT3 (right) and observed by immu-
nohistochemistry 14 days after grafting. Yellow arrows indicate hTH-positive cells. Inset represents magnification of TH-positive cell to observe
morphology. Scale bar = 50 mm. (F): Quantification of TH expression 1 and 14 days after grafting of NSCs and MIAMI cells alone and combined
with PAMs. TH expression is veryweak 24 hours after grafting for NSCs andMIAMI cells. A slight increase in expressionwas observedwhen cells
were adherent to LM-PAM-NT3. At 14 days after grafting, TH expression had increased and was significantly different for NSC/LM-PAM-NT3
compared with the 2 other conditions at this time point. An increase in TH expression was also observed for MIAMI cells when adherent
to LM-PAM-NT3 (n = 3; p, p , .01). Abbreviations: D, day; GFP, green fluorescent protein; hMito, hMito, human-specific mitochondria;
hTH, human-specific tyrosine hydroxylase; LM, laminin; MIAMI, marrow-isolated adult multilineage inducible (cell); NSC, neural stem cell;
NT3, neurotrophin-3; PAM, pharmacologically active microcarrier.
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or tumorigenesis, was used, because primary NSCs of human or-
igin are difficult to obtain and face significant ethical barriers
[26, 29].
In the present study, we chose a new ex vivomodel of PD able
to mimic the early and late disease stages to better understand
the efficacy and mode of action of stem cells to neuroprotect
the nigrostriatal pathway [23, 24]. The novelty of the present
work resides, in part, in using organotypic cultures to elucidate
mechanisms of neuroprotection or repair mediated by stem cells
alone or combined with PAMs, because only a small number of
studies have explored this possibility. To be able to implant
PAM/cell complexes in the brain slices, Stoppini’s membrane in-
terface air-medium method was selected. This method allows
better access and observation of the cultured tissue but also
amore limited survival time [37]. The degeneration of the nigros-
triatal pathway obtained here was not accompanied by the
formation of Lewy bodies in the dying neurons. Despite those
limitations, organotypic cultures can be very useful to better elu-
cidate the mechanisms by which stem cell therapy, combined or
not, with drug delivery can exert beneficial effects, because cell
graft-host tissue cross-talk is present, and they can be kept in cul-
ture for a fewweeks,maintaining the cytoarchitecture of theorig-
inal tissue [23].
In the present study, we first showed that released NT3 from
PAMswas bioactive. The released NT3 possessed a strong neuro-
nal differentiation capacity on DRG cells at a low dose (approxi-
mately 5 ng/ml), confirming that sufficient amounts of NT3
were released to induce stem cell survival/differentiation. More-
over, cell differentiation was maintained until the end of the ex-
periment in the presence of released NT3. This allowed an
important therapeutic window for the MIAMI cells and NSCs to
differentiate toward a neuronal phenotype and to explore repair
mechanisms.
Stem cell transplants were performed 2 days after organo-
typic slice preparation (Fig. 1A), when approximately 80% of
the TH-positive neurons in the substantia nigra and 30% of dopa-
minergic fibers in the striatum had degenerated [24], mimicking
an early stage of PD. We first confirmed our previous in vivo
observations, showing a significant striatal dopaminergic fiber
protection/repair after MIAMI/LM-PAM-NT3 grafting [12]. Al-
though the amount of PAMs and cells injected was less in this ex
vivo paradigm, clear protection/repair was observed. Moreover,
the effect was observed 14 days after grafting, which is a short time
window to observe a complete regenerative process (usually
evaluated 4 [38] and 8 [12] weeks after implantation in hemipar-
kinsonian rats). Furthermore, neuroprotection of the MFB fibers
was also observed after MIAMI/LM-PAM-NT3 grafting. The
degree of protection was, however, less prominent after
NSCs/LM-PAM-NT3 grafting, which was somewhat similar to
that of LM-PAM-NT3 not conveying any cells. The NT3 anti-
apoptotic role in 6-OHDA-treated PC12 cells [39] and its neuro-
protective effects on the nigrostriatal pathway in the adult rat
model of PD [40] have been previously reported. Although
NT3 can increase the survival of grafted ventral mesencephalic
cells in rat striatum, it does not significantly increase host TH
staining, which was confirmed in our study by the lack of TH
staining in the MFB after LM-PAM-NT3 grafting [41]. In addition,
a weak spontaneous dopaminergic reinnervation of the striatum
was also observed, as previously described [42].
The grafted cells acquired a neuronal-like morphology
2weeks after grafting, suggesting integration into the host tissue.
Nevertheless,b3-tubulin expressionbyNSCswashigher than that
by MIAMI cells at all times, confirming that NSCs spontaneously
differentiate into neuronal cells in vivo [28, 29]. The neuronal dif-
ferentiation was further enhanced for both types of cells by LM-
PAM-NT3. These results confirm the combined action of laminin
and NT3 on the increase of b3-tubulin MIAMI cell expression ex
vivo, as previously observed in vitro [9]. A significant increase in
THexpressionwasnoticed forNSCswhen theyweregraftedalone
in the organotypicmodel of PD at day 14. Furthermore, LM-PAM-
NT3 enhanced TH expression for NSCs and MIAMI cells, and for
the latter, NT3 releasewas anessential factor. This differentiation
potential of stem cells has been observed despite a short time
window and should be further explored to understand their de-
gree of commitment toward the neuronal lineage. RT-qPCR per-
formed onMIAMI cells after epidermal growth factor (EGF)/basic
fibroblast growth factor (bFGF) treatment indicates that MIAMI
cells express Nurr1 mRNA during proliferation (data not shown).
These data, together with the previously published data in which
we observed increased Nestin, Pax 6, and Ngn2 expression [10],
suggest that EGF/bFGF pretreated cells might be engaged into
a “neuronal dopaminergic precursor” phenotype. Furthermore,
slight hTH protein expression has been found by Western blot
in hNS1 cells culturedunder proliferative conditions, in particular,
in low oxygen tension conditions (data not shown), confirming
that hNS1 have a slight basal expression of TH in proliferation
[27]. However, injection of the cells within the striatum, in partic-
ular, in the damaged striatum, can accelerate this TH induction.
This dopaminergic inductive effect of the striatum has also been
described both in vitro and in vivo [30, 43–46]. In a previous study
using hNS1 cells, 25%ofmature dopaminergic neurons able to se-
crete dopamine were found after only 12 days of coculture with
lesioned striata [30].
A remarkable increase of DA content in the striatum, which
reached normal levels, was observed after NSC/LM-PAM-NT3
grafting. In this case, DA was most likely released by differenti-
ated, more mature NSCs, because a significant restoration of
the host dopaminergic pathway was not observed with these
cells. The high NSC survival rate might have contributed to
the striatal DA restoration observed in our study. All these data
suggest that NSC grafts combinedwith LM-PAM-NT3 exert their
beneficial effect by a cell replacement mechanism. In contrast,
after MIAMI/LM-PAM-NT3 grafting, a slight increase in DA con-
tent in the striatum occurred that could have resulted from the
significant repair/protection of the host dopaminergic path-
way. MIAMI cells and, in particular, MIAMI cell/LM-PAM-NT3
complexes might exert neuroprotective effects on the nigros-
triatal pathway through their potential to secrete tissue repair
factors [12, 19]. Our study demonstrates that MIAMI cells
expressed BDNF and GDNF and high levels of hVEGFA mRNA
in vitro and ex vivo, confirming our previous results showing el-
evated levels of hVEGFA, significantly higher than for hMSCs
[11]. All three dopaminotrophic factors are known for their neu-
rotrophic properties and their ability to act on nigrostriatal DA
neurons [47–49]. NSCs expressed lower levels of hVEGFA and
mainly secreted hSTC1 in the organotypic culture model of
PD. Moreover, in our paradigm, MIAMI cells secreted approxi-
mately 100 pg/ml VEGFA; thus, it has been proved that neuro-
protection in PD was more efficient with a low secretion of
VEGFA (close to 1 ng/ml) and can even be deleterious at higher
doses (close to 100 ng/ml) [50]. In addition, a graft of an
hVEGFA-expressing cell line in parkinsonian rats induced strong
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behavioral recovery and protection of the nigrostriatal pathway
[47, 51, 52]. It was observed that VEGFA secretion is significantly
reduced over time after LM-PAM-NT3 adhesion of MIAMI cells,
but this condition gives the most significant neuroprotection of
the striatal dopaminergic fibers. These results can be explained
by a probable cumulative effect between hVEGFA secreted by
MIAMI cells and NT3 released by PAMs, because both have
neuroprotective and proangiogenic properties [53–55]. It can
Figure 5. Ex vivo mRNA and protein expression of cells grafted alone or adhering to PAMs. (A): hNS1 cells complexed to PAMmRNA expression in fold
increaseagainsthNS1cells implantedalone.GDNF,NGF,andtumornecrosis factor-a-stimulatedgene6(TSG6)werenotexpressed. (B):mRNAexpression in
fold increaseofMIAMIcellscomplexedtoPAMscomparedwithMIAMIcells implantedalone.TSG6wasnotexpressed,andSTC-1wasonlyslightlyexpressed.
(C):VEGFAmRNAexpressioninfoldincreaseofMIAMIcellscomparedwithNSCsinthesameconditions.MIAMIcellsexpressed4–10-foldmoreVEGFAmRNA
thandidhNS1cells. (D):STC-1mRNAexpressioninfold increaseofhNS1comparedwithMIAMIcells inthesameconditions.hNS1cellsexpressed40–100-fold
more STC-1mRNA than didMIAMI cells. (E): Enzyme-linked immunosorbent assay (ELISA) quantification of secreted STC-1 in culturemedium of stem cell-
graftedorganotypicslices.STC-1secretiondecreasedsignificantlyovertime(n=3;p,p, .05). (F):ELISAquantificationofsecretedVEGFAinculturemediumof
stemcell-graftedorganotypicslices.ForMIAMIcells,VEGFAsecretiondecreasedovertimeandwaslowerwithPAMadherencecomparedwithcellsalone.For
NSC cells, VEGFA secretion remained very low (n = 3; p, p, .05). Abbreviations: D, day; GDNF, glial cell line-derived neurotrophic factor; HGF, hepatocyte
growth factor; hNSCs, human neural stem cells; LM, laminin; MIAMI, marrow-isolated adult multilineage inducible (cell); NGF, nerve growth factor; NSC,
neural stem cell; NT3, neurotrophin-3; PAM, pharmacologically active microcarrier; SCT-1, stanniocalcin-1; VEGFA, vascular endothelial growth factor A.
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also be assumed that VEGFA binds to its own receptors and thus
will no longer be found in the culture media.
The importance of LM-PAMs has been highlighted in the pres-
ent study. MIAMI cells implanted alone induced a recovery of 30%
of rat striatal TH. The association of MIAMI cells with LM-PAMs
doubled survival and, as a consequence, doubled the level of striatal
rat TH. This showed that the MIAMI cells themselves induce
protection/repairof theTH+ fibersbyVEGFAsecretion.Furthermore,
MIAMI/LM-PAM-NT3 induced an increase of 24% of the rat TH level
compared with MIAMI/LM-PAM, indicating that NT3 and VEGFA
might act in association togive the77%TH+ fibersof thenigrostriatal
pathwaydetected inourstudy,becauseNT3alonecanonlygive67%.
No changewas found in the blood vessel number over time in
the organotypic slices treated with NSCs, which did not secrete
hVEGFA. NSCs differentiated toward TH-expressing cells able to
secrete DA, which can block hVEGFA expression [56]. In contrast,
vascularization was enhanced by VEGF-secreting MIAMI cells,
particularly when the cells were complexed to LM-PAM-NT3. An-
giogenesis induction by VEGFA in hippocampal slice cultures had
been previously described, suggesting that angiogenesis might
occur inourparadigm, parallel tomaintenanceof thebloodvessel
number [57]. However, hVEGFA secretion decreased over time
when the cells were grafted alone or were adherent to PAMs,
in which case they already expressed lower hVEGFA levels, prob-
ably owing to MIAMI cell differentiation into neuron-like cells
expressing TH [56]. Significant expression of the angiogenic factor
HGFwas detected inMIAMI cells, indicating that this factormight
also mediate the increase of CD31-expressing cells. In our model,
Figure 6. Paracrine stem cell-mediated effect of human vascular endothelial growth factor A on rat endothelial cells. (A): Immunofluorescence
against rat-specific CD31 in the striatum. A disappearance of blood vessels was observed in degenerated slices and after NSC/LM-PAM-NT3
implantation compared with intact slices. After NSC/LM-PAM-NT3 implantation, no blood vessels were observed. The blood vessel number
increased after MIAMI/LM-PAM-NT3 implantation. White arrows show the blood vessels, and asterisks indicate PAMs. Scale bar = 50 mm.
(B): Quantification of blood vessels in the slice. At day 4, no blood vessels were detected. No amelioration was observed after grafting NSCs
even when complexed with PAMs, but a significant protection of blood vessels was observed after MIAMI cell implantation, particularly when
adherent to LM-PAMs-NT3 (n = 3; p, p, .05). Abbreviations: D, day; LM, laminin; MIAMI, marrow-isolated adult multilineage inducible (cell);
NSC, neural stem cells; NT3, neurotrophin-3; PAM, pharmacologically active microcarrier.
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VEGFA will mainly act by a direct neuroprotective effect on the
cells and will probably have a protective effect via angiogenesis
on grafted cells in in vivo models. Indeed, vascularization of
grafted tissue and its integration into the host circulatory system
is needed for graft survival [58, 59]. However, certain studies have
shown that VEGFAcan alsobe effective in later disease stages [47,
60]. Although it is still controversial, a blood vessel defect might
be an additional contributing factor to the development of PD
[61]. In addition, increased angiogenesis can be associated with
an improvement of motor capacity in in vivo PD models [62].
The increased number of cells observed 1 day after grafting when
complexed to PAMs might also explain the neuroprotective
effects of these complexes, because more neuroprotective
factors might be secreted at this early time point. The in-
creased survival induced by PAMs might be also result from
the three-dimensional scaffolds [22]. The enhancement of
survival when cells are attached to a three-dimensional sub-
strate has been reported previously for retinal pigmental
epithelium cells [63], which led to a clinical trial in a PD
paradigm [64]. In contrast, no significant increase in NSC sur-
vival was detected with the 3D scaffold. However, NSC sur-
vival remained higher than that of MIAMI cells at any time.
STC-1 highly secreted by NSCs might act by autocrine mech-
anisms to induce cell protection against the mitochondrial
membrane defects induced by reactive oxygen species, such
as has been reported with neural crest-derived cells [65].
Moreover STC-1 can increase microtubule-associated protein
2c expression, an axon specific marker, in neuroblastoma cells.
Thus, STC-1 could be in part responsible for NSC neuroprotection
but also could increase neuronal differentiation by an autocrine
action [66]. Although the molecules we examined represent at-
tractive mediators of the mechanisms discussed, our studies do
not exclude the possibility that other molecules might also be
playing mechanistic roles.
Taken together, those findings show that those stemcells have
differentmodes of action that are clearly complementary. It would
be interesting to study the beneficial effect of both types of cells
grafted togetherwith LM-PAM-NT3,because it haspreviouslybeen
reported that hMSCs can increase survival of NSCs and neuropro-
tection in a Huntington’s disease paradigm [67] and that MSCs
might protect NSCs from oxidopamine-induced apoptosis [68].
CONCLUSION
Using an ex vivo model of PD, we showed that PAMs enhanced
the survival and neuronal differentiation of NSCs and MIAMI
cells to induce neuroprotection of the nigrostriatal pathway.
Moreover, NSCs might act through direct replacement of
loss/damaged cells for PD treatment, and MIAMI cells might
protect the host’s remaining dopaminergic cells by a paracrine
mechanism that could involve support both to the neural and to
the vascular compartments. Our findings have improved our
understanding of the stem cell neuroprotection mechanisms.
Taken together, our findings show a prospective interest of
both types of cells combined with LM-PAM-NT3 in tissue engi-
neering for PD.
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